FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• FTY720 (fingolimod) is an immunosuppressant with preclinical antitumor activity.
• Its specific mechanisms in glioblastoma treatment remain largely uncharacterized.

Purpose of the Study:

• To elucidate the mechanisms by which FTY720 affects human glioblastoma cells.
• To investigate the roles of apoptosis, necroptosis, and autophagy in FTY720's action.

Main Methods:

• Induction of apoptosis, necroptosis, and autophagy in human glioblastoma cell lines.
• Utilized RNA interference and chemical inhibitors to block autophagy.
• Investigated the involvement of the reactive oxygen species-c-Jun N-terminal kinase-protein 53 (ROS-JNK-p53) pathway and upstream receptor-interacting protein 1 and 3 (RIP1 and RIP3).
• Examined the effects of phosphorylated FTY720.
• Validated findings in vivo using glioblastoma xenograft mouse models.

Main Results:

• FTY720 induced extrinsic apoptosis, necroptosis, and autophagy in glioblastoma cells.
• Autophagy inhibition reduced FTY720-induced apoptosis and necrosis.
• The ROS-JNK-p53 loop, upstream of RIP1/RIP3, mediated these effects via the PI3K/AKT/mTOR/p70S6K pathway.
• Phosphorylated FTY720 induced autophagy but not apoptosis or necroptosis.
• In vitro findings were confirmed in vivo.

Conclusions:

• FTY720 triggers a complex interplay of apoptosis, necroptosis, and autophagy in glioblastoma.
• The ROS-JNK-p53 signaling axis is crucial for FTY720-mediated cell death and autophagy.
• These findings offer new mechanistic insights into FTY720's potential as a glioblastoma therapeutic agent.